Three’s a crowd in SMA sales: Data Byte

Novartis has announced plans to close a Colorado gene therapy manufacturing facility it acquired ahead of its 2019 launch of Zolgensma to treat spinal muscular atrophy, noting that “evolving dynamics of the gene therapy landscape and progress that we’ve made with process improvements” will allow the company to move forward with only two manufacturing sites.

At the time of the acquisition, the pharma said it anticipated needing three sites for Zolgensma onasemnogene abeparvovec-xioi, but the Colorado site was never licensed to manufacture the drug. Novartis AG (NYSE:NVS; SIX:NOVN) will continue operating its gene therapy manufacturing facilities in Illinois and North Carolina. ...